An independent two-stage DCF analysis by a frontier AI model.
Medtronic is a foundational player in the global medical device industry, boasting a diversified portfolio that touches millions of patients annually across 150+ countries. Despite its wide economic moat and strong cash generation (over $4B in FCF), the company has struggled with inconsistent execution and sluggish growth in recent years. Management's current focus on restructuring and reallocating capital toward higher-growth opportunities is a necessary step to unlock value.
Our valuation model assumes a conservative recovery trajectory, projecting modest 5% free cash flow growth as new products gain traction and cost-saving initiatives take hold. While Medtronic may lack the explosive growth of some smaller medtech peers, its compelling 3.27% dividend yield and current forward P/E of 14.2x offer a reasonable entry point for patient investors seeking stability and eventual operational improvement.
The 5.0% growth rate assumption reflects our balanced view on the company's ability to grow free cash flow over the next 5 years.
A 8.0% discount rate is applied to reflect the risk profile and cost of capital.
The 2.5% terminal growth rate is consistent with long-term macroeconomic expectations.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 1.5% | $87.84 | $71.87 | $60.81 | $52.70 | $46.50 |
| 2.0% | $98.82 | $79.06 | $65.88 | $56.47 | $49.41 |
| 2.5% | $112.94 | $87.84 | $71.87 | $60.81 | $52.70 |
| 3.0% | $131.76 | $98.82 | $79.06 | $65.88 | $56.47 |
| 3.5% | $158.11 | $112.94 | $87.84 | $71.87 | $60.81 |
■ Undervalued vs current price ■ Overvalued vs current price
A 5.0% growth rate assumes Medtronic successfully executes its turnaround strategy, stabilizing market share and driving moderate growth through new product introductions like Hugo and its latest diabetes systems.
The 8.0% discount rate reflects Medtronic's overall stability (beta of 0.73) and strong cash flow generation, balanced against the execution risks associated with its ongoing restructuring and competitive pressures.
While the DCF strictly models free cash flow, Medtronic's strong 3.27% dividend yield is supported by the very cash flows projected in this model, making it a key component of the overall investment thesis.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.